Switch theme
Sign up to access all valuation multiples
AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines. The company operates within India, and outside, like Cambridge, Gothenburg, and Gaithersburg. The majority of revenue is from India.
1979
802
Last FY Revenue $196M
Last FY EBITDA $22.6M
$2.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, AstraZeneca India achieved revenue of $196M and an EBITDA of $22.6M.
AstraZeneca India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AstraZeneca India valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $196M | XXX | XXX | XXX |
| Gross Profit | XXX | $81.5M | XXX | XXX | XXX |
| Gross Margin | XXX | 42% | XXX | XXX | XXX |
| EBITDA | XXX | $22.6M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 12% | XXX | XXX | XXX |
| EBIT | XXX | $24.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 13% | XXX | XXX | XXX |
| Net Profit | XXX | $13.2M | XXX | XXX | XXX |
| Net Margin | XXX | 7% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, AstraZeneca India's stock price is INR 8291 (or $95).
AstraZeneca India has current market cap of INR 207B (or $2.4B), and EV of INR 202B (or $2.3B).
See AstraZeneca India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.3B | $2.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, AstraZeneca India has market cap of $2.4B and EV of $2.3B.
AstraZeneca India's trades at 12.6x EV/Revenue multiple, and 97.6x EV/EBITDA.
Equity research analysts estimate AstraZeneca India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AstraZeneca India's P/E ratio is not available.
See valuation multiples for AstraZeneca India and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.3B | XXX | $2.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 12.6x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 97.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 99.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 163.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 389.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAstraZeneca India's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
AstraZeneca India's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AstraZeneca India's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AstraZeneca India and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AstraZeneca India acquired XXX companies to date.
Last acquisition by AstraZeneca India was XXXXXXXX, XXXXX XXXXX XXXXXX . AstraZeneca India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was AstraZeneca India founded? | AstraZeneca India was founded in 1979. |
| Where is AstraZeneca India headquartered? | AstraZeneca India is headquartered in India. |
| How many employees does AstraZeneca India have? | As of today, AstraZeneca India has 802 employees. |
| Is AstraZeneca India publicy listed? | Yes, AstraZeneca India is a public company listed on BOM. |
| What is the stock symbol of AstraZeneca India? | AstraZeneca India trades under 506820 ticker. |
| When did AstraZeneca India go public? | AstraZeneca India went public in 2001. |
| Who are competitors of AstraZeneca India? | Similar companies to AstraZeneca India include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of AstraZeneca India? | AstraZeneca India's current market cap is $2.4B |
| Is AstraZeneca India profitable? | Yes, AstraZeneca India is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
